Development for the Peritoneal Carcinomatosis Index (PCI) in Ovarian Cancer

* Primary objectives: To develop peritoneal carcinomatosis index (PCI) for ovarian cancer, tubal cancer and primary peritoneal cancer that can represent perioperative intraperitoneal tumor burden objectively * Secondary objectives: To establish the relationship and find out clinical significance between PCI, tumor location and tumor characteristics

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Ovarian Cancer Adnexal Diseases Endocrine Gland Neoplasms Endocrine System Diseases Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Genital Diseases Genital Diseases, Female Genital Neoplasms, Female Gonadal Disorders Neoplasms Neoplasms by Site Ovarian Diseases Ovarian Neoplasms Urogenital Diseases Urogenital Neoplasms

Sex eligibility

Female

Study type

Observational

Primary location

National Cancer Center

Goyang-si, Gyeonggi-do, 410-769, South Korea

About this study

Patients with primary ovarian cancer

Informed consent
Digital photography & Checking PCI (tumor size, number, and Characteristics)
Postoperative surveillance(tumor marker, image and physical examination)

Developing the best fitting PCI model to reflect recurrence-free survival and overall survival

Selection of items
Weighting by items and tumor characteristics
Analysis of prognostic impact of PCI compared to conventional staging system (FIGO stage) for ovarian cancer

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Preoperative clinical diagnosis of ovarian cancer, tubal cancer, and primary peritoneal carcinoma (all stage)
Available preoperative image study (CT and/or MRI and/or PET)
Patients who gave a written informed consent
Patients must be surgical candidate considering medical and psychological condition

Exclusion criteria

Patients who refuse to participate or want to withdraw at anytime.

Treatment and study plan

Primary outcomes

Devleopment for the peritoneal carcinomatosis index (PCI)

Time frame: 55 months

Sponsors and collaborators

Lead sponsor

National Cancer Center, Korea

Other Gov

Registry information

Official study title

A Clinical Trial to Develop a Peritoneal Carcinomatosis Index (PCI) in Ovarian

Important dates

Study start: 2008
Primary completion: 2012
Study completion: 2013
First posted: Feb 24, 2012
Registry last updated: Mar 28, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed